Celerion
Lincoln, Nebraska, 68502, United States
NCT Number: NCT03408470
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects. Subjects in cohort 1 will receive a single oral dose of TD-1473 and a single intravenous bolus dose of [14C]-TD-1473. Subjects in cohort 2 will receive a single oral dose of [14C]-TD-1473 only.
Looking for future studies?
Notify Me19 year–55 year
Male
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(Intervention description included in arm description)
(Intervention description included in arm description)
(Intervention description included in arm description)
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
Time frame: Up to 15 days
TD 1473 metabolite profiling will be performed in plasma containing sufficient amounts of radioactivity
Time frame: Up to 15 days
TD 1473 metabolite profiling will be performed in urine containing sufficient amounts of radioactivity
Time frame: Up to 15 days
TD-1473 metabolite profiling will be performed in feces containing sufficient amounts of radioactivity
Theravance Biopharma
Industry
A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04587713
Bowel Diseases, Inflammatory, Digestive System Diseases
Cypress, California, United States
View Trial DetailsNCT00640809
Bowel Diseases, Inflammatory, Digestive System Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT05043363
Bowel Cancer, Bowel Diseases, Inflammatory
London, United Kingdom
View Trial DetailsNCT02647866
Abdominal Pain, Autoimmune Disease
Greenville, South Carolina, United States
View Trial Details